A detailed history of Pointe Capital Management LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Pointe Capital Management LLC holds 341 shares of REGN stock, worth $251,658. This represents 0.21% of its overall portfolio holdings.

Number of Shares
341
Holding current value
$251,658
% of portfolio
0.21%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$1024.09 - $1201.76 $349,214 - $409,800
341 New
341 $358,000
Q1 2023

May 12, 2023

BUY
$680.49 - $826.97 $89,824 - $109,160
132 New
132 $108,000
Q1 2022

May 13, 2022

BUY
$595.12 - $698.43 $8,331 - $9,778
14 Added 2.51%
571 $399,000
Q4 2021

Feb 11, 2022

BUY
$543.48 - $670.97 $302,718 - $373,730
557 New
557 $352,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $79.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Pointe Capital Management LLC Portfolio

Follow Pointe Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pointe Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pointe Capital Management LLC with notifications on news.